Novartis has revealed its intent to file anti-VEGF therapy Lucentis for retinopathy of prematurity (ROP), a rare disease in premature infants that often leads to blindness.
24th September 2018
The European Commission (EC) has granted marketing authorisation for Pierre Fabre’s Braftovi and Mektovi combination therapy for the treatment of adults with unresectable or metastatic melanoma with a BRAFV600 mutation.
24th September 2018
Marking a bumper month for Committee for Medicinal Products for Human Use (CHMP) decisions, 13 medicines have been put forward for approval in the region, including three orphan medicines.
24th September 2018
Bayer and Novartis have lost a landmark case in the UK seeking to prevent the off-label use of Roche’s Avastin to treat wet AMD, a leading cause of sight loss in the elderly.
24th September 2018
New from PharmaTimes Media is the Medical & Scientific Excellence Awards.Highlighting this important area of work within the pharmaceutical industry, the awards are designed to recognise the outstanding achievements of medical and scientific professionals.
21st September 2018
Bedrock, DDB Remedy and Insypher lead the agency field, Gilead tops the pharma chart
21st September 2018
The Association of the British Pharmaceutical Industry (ABPI) is linking arms with the Academic Health Science Network in a five-year partnership that strives to accelerate uptake of transformative biomedical innovations by the NHS
21st September 2018
Celgene has decided not to exercise its option to license OncoMed's bispecific antibody navicixizumab.
21st September 2018
Daiichi Sankyo has entered into a clinical trial collaboration agreement with a subsidiary of MSD to evaluate a potential new combination therapy for breast or lung cancers.
21st September 2018
Cancer Research UK is partnering with European cancer research charities AIRC (Associazione Italiana per la Ricerca sul Cancro) and FC AECC (Asociación Española Contra el Cáncer) to invest around £30 million in six international collaborations aiming to accelerate progress in translational research.
20th September 2018
US regulators have turned down Pharming’s application to expand the approved uses of Ruconest to include prophylaxis in patients with hereditary angioedema (HAE).
20th September 2018
The European Commission has approved Mylan and Fujifilm Kyowa Kirin Biologics’ Humira biosimiar Hulio.
20th September 2018
A Phase III study assessing Astellas’ roxadustat in patients with chronic kidney disease (CKD) and anaemia who are not receiving dialysis has met its key endpoints.
20th September 2018
Swiss group Addex Therapeutics has joined a UK-based initiative established to study the role of the D1 receptor, the main dopamine receptor, in human brain function.
20th September 2018
Norgine has signed a deal with Shield Therapeutics allowing it to commercialise iron deficiency therapy Feraccru in Europe, Australia and New Zealand.
19th September 2018
